Oramed Pharmaceuticals to Present at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia, PA, June

   Oramed Pharmaceuticals to Present at the 72nd Scientific Sessions of the
      American Diabetes Association in Philadelphia, PA, June 8-12, 2012

PR Newswire

JERUSALEM, June 4, 2012

JERUSALEM, June 4, 2012 /PRNewswire/ --

Oramed Pharmaceuticals (OTCBB: ORMP.OB), a developer of oral delivery
systems, announced today that its abstract, "Concomitant oral insulin and
exenatide therapies significantly curb postprandial glucose in pigs," which
reports on the impact of its oral insulin capsule (ORMD-0801) delivered in
combination with its oral exenatide capsule (ORMD-0901), has been accepted for
presentation at the 72^nd Scientific Sessions of the American Diabetes
Association (ADA). The work to be presented assessed the safety and
effectiveness of a combination of oral insulin and oral exenatide treatments
delivered to pigs prior to food intake. The drug combination resulted in
significantly improved blood glucose regulation when compared to
administration of each drug separately. Dr. Miriam Kidron, Chief Scientific
Officer at Oramed Pharmaceuticals, will be presenting the poster on Sunday,
June 10, 2012, at 11:30am-1:30pm (EDT).

For additional information on the upcoming ADA conference, please visit their
website: http://professional.diabetes.org/Default.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via
injection.Established in 2006, Oramed's technology is based on over 25 years
of research by top research scientists at Jerusalem's Hadassah Medical Center.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering
Phase 2a trials. The company's corporate and R&D headquarters are based in
Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Company and Investor Relations Contact:
Aviva Sherman
USA: +1-646-240-4193
Int'l: +972-2-566-0001
+972-54-792-4438
E-mail: aviva@oramed.com

SOURCE Oramed Pharmaceuticals
 
Press spacebar to pause and continue. Press esc to stop.